ERGOMED

News

London, UK, December 4, 2017

Ergomed’s PrimeVigilance hosts prestigious intelligent automation seminar for the International Society of Pharmacovigilance

– PrimeVigilance hosting Intelligent Automation in Pharmacovigilance seminar in Cambridge, MA, 4-5 December
– Jan Petracek, CEO of PrimeVigilance, presenting The optimal service mix for 2020

London, UK – 4 December 2017: Ergomed plc (LSE: ERGO) (‘Ergomed’ or the ‘Company’), a specialised pharmaceutical services and drug development company, today announces that its pharmacovigilance subsidiary PrimeVigilance will be organising…


London, UK, 23 October 2017

Ergomed’s first-in-class haemostat, PeproStat™, reports positive top-line results and meets key endpoints in Phase II study

–     Highly innovative blood free haemostat met the primary efficacy endpoint of superiority over standard of care in time to haemostasis with statistical significance across all surgery types tested

–     PeproStat was seen to be safe with no treatment related SAEs reported and no re-bleeding

–     PeproStat™ demonstrated superiority in…


London, UK, October 3, 2017

Completion of Acquisition of PSR Group BV, a specialist orphan drug CRO

London, UK – 3 October 2017: Ergomed plc (AIM: ERGO) (“Ergomed” or the “Company”), is pleased to announce that, further to the Company’s announcement on 28 September 2017, the acquisition of PSR Group BV (“PSR”) has completed following the admission to trading on AIM of the 2,081,389 new ordinary shares of 1p each at…


London, UK, 28 September 2017

Acquisition of PSR Group BV, a specialist orphan drug CRO, for consideration of up to €5.7 million

Acquisition of PSR Group BV, a specialist orphan drug CRO, for consideration of up to €5.7 million

and

Placing to raise £2.9 million

  • Acquisition moves Ergomed towards leadership in orphan drug development services
  • PSR’s specialist orphan drug development business will complement Ergomed’s existing strong expertise in this area
  • PSR will expand Ergomed’s services…

London, UK, 27 September 2017

Ergomed Signs First Commercialisation Deal for Haemostatix Products

Boryung Pharmaceutical Co.Ltd licenses PeproStat and ReadyFlow for commercialisation in South Korea

Ergomed to receive an upfront and future milestone payments as well as double-digit share of product sales

Deal driven by British innovation in the treatment of surgical bleeding with multi-million dollar potential

London, UK / Seoul, Republic…


Page 2 of 1912345...10...Last »
Translate »